Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 12/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21076960 | 0.84 | CYP1A2 (0.40) | CYP1A2SCN5A | |
| SCHEMBL20190553 | 0.79 | CYP1A2 (0.49) | CYP1A2SCN5ASCN1ASCN2AALDH1A1 | |
| SCHEMBL18357673 | 0.75 | KDM4E (0.32) | CYP1A2 | |
| SCHEMBL17611609 | 0.75 | CYP1A2 (0.46) | CYP1A2SCN5ASCN1ASCN2AALDH1A1 | |
| SCHEMBL31569340 | 0.74 | SCN5A (0.45) | CYP1A2SCN5A | |
| SCHEMBL13757316 | 0.73 | SCN5A (0.59) | CYP1A2SCN5ASCN1ASCN2AALDH1A1 | |
| SCHEMBL20203851 | 0.73 | CYP1A2 (1.00) | CYP1A2SCN5A | |
| SCHEMBL16946874 | 0.72 | PIM1 (0.41) | CYP1A2 | |
| SCHEMBL20400230 | 0.72 | KDM4E (0.40) | CYP1A2ALDH1A1 | |
| SCHEMBL20203995 | 0.71 | CYP1A2 (0.67) | CYP1A2SCN5ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059691-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | US | disclosed |
| EP-4255900-A2 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| US-7307164-B2 | β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | CYP1A2 1250/4885SCN5A 1294/4885SCN1A 3261/4885 |
| US-20240059691-A1 | ENZYME INHIBITORS | SERPINB1, XDH, ACE | CYP1A2 26/4885SCN5A 1309/4885SCN1A 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.